Logo Image
|Articles|November 6, 2015

Pediatric Drug Development & Therapeutics in October TIRS

Author(s)DIA

The Special Section on Pediatric Therapeutics in the November, 2015 issue of Therapeutic Innovation & Regulatory Science includes a series of articles on pediatric drug development and therapeutics - from new genomic targets for drug discovery, to new clinical trial paradigms, to formulation acceptability validation, to patient-centric global networks, to a comprehensive view of pediatric regulatory requirements. 

 

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
Read more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more